Tang Suoqin

Dr. Tang Suoqin’s pediatric oncology work spans both clinical treatment and translational research, including a Phase I/II trial presented in Nature Communications (2024) titled “A Phase I/II Trial.” As a specialist at the clinic, he is a Distinguished Professor and Senior Consultant in the Department of Hematology and Oncology at Beijing Jingdu Children’s Hospital. His profile describes more than 30 years of clinical and academic leadership focused on high-risk neuroblastoma and refractory pediatric solid tumors. His career also includes institutional leadership experience, including serving as Director of Pediatrics at the People’s Liberation Army General Hospital (PLAGH) before joining the clinic in the 2010s.

Work experience

• Distinguished Professor and Senior Consultant, Department of Hematology and Oncology — Beijing Jingdu Children’s Hospital.
• Director of Pediatrics — People’s Liberation Army General Hospital (PLAGH).

Clinical focus and techniques

Dr. Tang Suoqin’s clinical scope is pediatric oncology, with a focus on difficult-to-treat solid tumors where protocol-level decisions can affect outcomes.

• Complex treatment for neuroblastoma.
• Targeted therapy (described as part of his neuroblastoma treatment work).
• Immunotherapy work is referenced as part of his broader pediatric oncology framework.

Academic output

• Nature Communications (2024) — Phase I/II trial titled “A Phase I/II Trial.”

Courses and advanced training

No named courses are specified in the provided materials.

Awards and recognition

His profile highlights research and healthcare advocacy rather than named awards.

For families seeking pediatric oncology consultation, the clinic supports multidisciplinary evaluation and protocol-driven planning. Dr. Tang Suoqin’s focus includes high-risk neuroblastoma and refractory pediatric solid tumors, and his ongoing work aims to expand access to advanced therapies through AI-driven precision oncology platforms.